Inventor
CAO GUOQING
CN20 patents
⚠️ This page may combine multiple inventors who share the name “CAO GUOQING”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD
6 patentsUS11866500B2Jan 9, 2024
Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD1 citations72
US11208484B2Dec 28, 2021
Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD4 citations72
US11365255B2Jun 21, 2022
PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD2 citations71
US10815304B2Oct 27, 2020
PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD3 citations70
US12435144B2Oct 7, 2025
Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD0 citations61
US11780923B2Oct 10, 2023
PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD0 citations59
Shanghai hengrui pharmaceutical co ltd
4 patentsUS10344090B2Jul 9, 2019
PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
Shanghai hengrui pharmaceutical co ltd15 citations92
US10206980B2Feb 19, 2019
IL-15 heterodimeric protein and uses thereof
Shanghai hengrui pharmaceutical co ltd20 citations92
US9862765B2Jan 9, 2018
IL-17A binding agent and uses thereof
Shanghai hengrui pharmaceutical co ltd2 citations72
US9637484B2May 2, 2017
Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof
Shanghai hengrui pharmaceutical co ltd5 citations68
JIANGSU HENGRUI MEDICINE CO
4 patentsUS11525005B2Dec 13, 2022
Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
JIANGSU HENGRUI MEDICINE CO1 citations60
US11000518B2May 11, 2021
Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
JIANGSU HENGRUI MEDICINE CO0 citations57
US11065239B2Jul 20, 2021
Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumor
JIANGSU HENGRUI MEDICINE CO0 citations51
US11471503B2Oct 18, 2022
Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain
JIANGSU HENGRUI MEDICINE CO0 citations49